Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170103 | 0.78 | SAE1 (0.44) | MEN1KMT2AMMP2MMP3HTT | |
| SCHEMBL2590639 | 0.78 | BACE1 (0.47) | — | |
| SCHEMBL22099907 | 0.75 | EPHX2 (0.62) | MEN1KMT2AEPHX2 | |
| SCHEMBL23072506 | 0.74 | MAPT (0.41) | MEN1KMT2AHTTKDM4EGAA | |
| SCHEMBL27514070 | 0.73 | GSK3B (0.46) | MEN1KMT2AMMP2MMP3HTT | |
| SCHEMBL8223856 | 0.72 | PTGS2 (0.55) | MMP2MMP3KDM4EGAAMAPT | |
| SCHEMBL19002300 | 0.72 | GSK3B (0.44) | MEN1KMT2AHTTKDM4EGAA | |
| SCHEMBL2575820 | 0.72 | PTGS2 (0.55) | MMP2MMP3KDM4EGAAMAPT | |
| SCHEMBL20665306 | 0.71 | MAPT (0.44) | MEN1KMT2AMMP2MMP3HTT | |
| SCHEMBL8224397 | 0.71 | HTT (0.48) | MEN1KMT2AMMP2MMP3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1924561-B1 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-1924561-B1 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| EP-1924561-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR1A, HTR2A | CTSL 4497/4885CTSB 4291/4885CTSS 3913/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | CTSL 4497/4885CTSB 4291/4885CTSS 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.